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Abstract
Natural ligands of G-protein-coupled receptors interact with the orthosteric ligand binding site, as do
most of the classical synthetic ligands. The discovery of ligands targeting different, allosteric binding
sites considerably expanded the repertoire of G-protein-coupled receptor ligands. More recently,
bitopic ligands have been described that target both orthosteric and allosteric sites at the same time.
Introduction and context
G-protein-coupled receptors (GPCRs) constitute the
largest family of membrane proteins and are known to
respond to a plethora of different stimuli by activating
numerous intracellular signaling pathways. Because of
their involvement in a variety of biological processes,
GPCRs are the target of more than 50% of currently
marketed drugs [1]. To date, most of the drugs targeting
GPCRs are known to interact with the orthosteric site –
that is, the endogenous ligand-binding pocket [2]. These
orthosteric ligands need, however, to overcome many
limitations, such as decreased selectivity, insufficient
clinical efficacy, and undesirable effects on receptor
regulation [3].
The past decade witnessed the discovery of new
pharmaceutical compounds that modulate receptor
function by targeting allosteric sites. Allosteric sites are,
by definition, domains topographically distinct from the
orthosteric binding pocket [4]. These allosteric modula-
tors are very promising pharmaceutical drugs devoid of
many of the disadvantages of orthosteric ligands. In fact,
these allosteric compounds show higher subtype selec-
tivity (allosteric sites are generally less conserved than
orthosteric sites), often have a ‘safer’ pharmacological
profile (exert their effects only in the presence of
endogenous ligands) and, in some cases, do not induce
receptor desensitization [4].
There are three general categories of allosteric modu-
lators [3] (Figure 1a): first, modulators affecting the
binding affinity of orthosteric ligands, such as AMNO82,
which is responsible for the incomplete inhibition of
orthosteric antagonist binding to the metabotropic
glutamate (mGlu) 7 receptor, mGlu7R [5]; and second,
modulators affecting orthosteric ligand efficacy. One
example is CGP7930, which is known to enhance
gamma-aminobutyric acid receptor B (GABAB)-mediated
GTPS( g u a n o s i n e5
0-O-[gamma-thio]triphosphate)
binding [6]. Third, allosteric agonists and inverse
agonists, known to engender a unique GPCR conforma-
tion that alters receptor signaling in the absence of
orthosteric ligands [3,4]. For example, MPEP (2-methyl-
6-(phenylethynyl)pyridine) acts as a negative allosteric
modulator of mGlu5R by inhibiting inositol phosphate
production in the absence of an agonist [7]. Another
example is AC42, which was first identified as a selective
agonist of the M1 muscarinic acetylcholine receptor
(M1AChR) [8]; however, mutation studies have implied
that this ligand activates the receptor via an allosteric
site [9].
Recent advances
Recently, a new class of ligands, termed bitopic or
dualsteric ligands,which simultaneouslytargetorthosteric
and allosteric sites, emerged (Figure 1b). The develop-
ment of bitopic ligands is based on the idea of combining
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(via allosteric sites). Until now, muscarinic acetylcholine
receptors (mAChRs) have proved to be a particularly
fruitful receptor model for the development and char-
acterization of bitopic ligands. In 2004, Tahtaoui et al.
[10] synthesized seven fluorescent derivatives of the
BODIPY-labeled pirenzipine, an M1AChR antagonist,
andusedfluorescentresonance energytransfertechnology
to study receptor-ligand interactions. The authors showed
that these analogs might interact with both the acetylcho-
line (orthosteric) and brucine (allosteric) binding
domains of the M1AChR, therefore behaving as potential
bitopic ligands.
The literature also reports the design of hybrid molecules
from allosteric modulators of W84-type compounds
and orthosteric antagonists or agonists of mAChRs to
obtainsubtypeselectivemuscarinicligandswithagonistic
or antagonistic properties [11].
Inarecentpublication[12],Christopoulosandcolleagues
elegantly showed that McN-A-343, a selective M2AChR
partial agonist, is actually a bitopic ligand. Using several
different binding and functional assays, the authors
showed that McN-A-343 is composed of an orthosteric
agonist coupled to an allosteric modulator (3-chloro-
phenylcarbamate moiety). Truncated derivatives of
McN-A-343 retaining the chlorophenylcarbamate moiety
were positive modulators of the orthosteric antagonist
N-[3H]methylscopolamine in radioligand binding
assays,butinfunctionalassays,suchasM2AChR-mediated
ERK1/2 (extracellular signal-regulated kinase 1/2)
phosphorylation, they acted as negative modulators of
agonist efficacy.
Finally, in 2009, Antony et al. [13] presented a novel
approach to pharmacologically design subtype and
signaling selective receptor agonists, once again using
the mAChRs as templates. Their paper reports the
synthesis of two hybrids fusing a highly potent
oxotremorine-like orthosteric activator with M2-selec-
tive bis(ammonio)alkane-type allosteric fragments.
Radioligand binding in wild-type and mutant receptors
supplemented by receptor docking simulations showed
an M2-selective and true allosteric/orthosteric binding.
Moreover, G-protein activation, in this context, was
mediated by the orthosteric moieties. Interestingly,
hybrid compounds showed ligand-biased signaling
properties.
Future directions
Due to the unique features of bitopic ligands, their
number is likely to expand in the near future. This may
include the re-examination of already existing ligands, as
was the case with McN-A-343[12], and the de novo design
of bitopic ligands as shown by Antony et al. [13]. Where
can we expect to see the fastest progress? The number of
already existing ligands that might turn out to be bitopic
is difficult to estimate and will strongly depend on the
degree of information available for these putative bitopic
molecules. However, most progress is expected to come
from newly designed ligands.
Figure 1. Different binding modes of orthosteric, allosteric,
and bitopic ligands
(a) An allosteric ligand may modulate binding (1) and signaling (2) of
orthosteric ligands or (3) induce signal transduction by its own
(allosteric agonists) (adapted from Langmead and Christopoulos [3]).
(b,c) Comparison of different binding modes of orthosteric (red circle) and
allosteric (red triangle) ligands as monovalent ligands (b) or bivalent bitopic
ligands (c). Binding of orthosteric ligands induces Signal 1, which can be
modulated by allosteric ligands binding to sites that are close to or distant
from the orthosteric binding site, generating Signal 1* or Signal 1**.
Alternatively, the signal generated by the orthosteric ligand in one protomer
can be allosterically modulated by the other protomer within a GPCR
dimer, generating Signal 1***. Allosteric agonists can induce signaling by
their own in the absence of orthosteric ligands (Signal 2). Signals 1*, 1**, and
1*** can also be generated by bitopic ligands. In addition, bitopic ligands
could induce signals (Signals 1’,1 ’’, and 1’’’) that are specific for these ligands
and not observed upon simultaneous stimulation with monovalent
orthosteric and allosteric ligands.
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knowledge about orthosteric and allosteric ligands
available for a given GPCR as well as its ligand binding
sites. This may explain the fact that bitopic ligands have
predominantly been described for muscarinic receptors,
for which detailed knowledge on allosteric binding sites
and ligands is indeed available. Once allosteric ligands
have been identified, the choice of an optimal linker has
to be considered. The extensive literature on the design
and synthesis of bivalent ligands intended to target two
orthosteric ligand binding sites within a GPCR dimer
will be a rich source of inspiration for the synthesis of
bitopic ligands [14]. As illustrated by compound McN-A-
343 and hybrid compounds described by Antony et al.
[13], linker length can vary considerably even for the
same receptor. Obviously, the better the structural
knowledge about orthosteric and allosteric binding
sites, the easier the rational design of the linker (chemical
nature and length of linker, linker attachment point to
pharmacophores) will be.
Recently solved GPCR structures will assist the design and
synthesis of bitopic ligands that bind to identified
orthosteric and allosteric binding pockets. Such GPCR
structures have not only provided detailed knowledge
about orthosteric binding pockets, but also revealed the
important role of extracellular receptor domains in
guiding small molecular weight ligands to their high
affinity ligand binding pockets within the transmembrane
domain [15]. These ‘ligand entrance channels’ are inter-
esting new targets for allosteric modulation by bitopic
ligands.Finally,theconcept ofbitopicligandsmayalsobe
extended to GPCR dimers, where the orthosteric and
allosteric pharmacophores bind to two different proto-
mers in the receptor dimer (Figure 1b) [14].
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